Healthcare entity
They are less corroborated than the beat average, carrying 2.5 original sources each against 4.2 for the same window. Delhi High Court is the most frequent co-covered peer, appearing in 1 of the 4 tracked stories. That works out to roughly 0.2 stories per week across a 135-day span.
Last mentioned: Mar 18, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
They are less corroborated than the beat average, carrying 2.5 original sources each against 4.2 for the same window. Delhi High Court is the most frequent co-covered peer, appearing in 1 of the 4 tracked stories. That works out to roughly 0.2 stories per week across a 135-day span. regulation accounts for 2 of the 4 tracked stories, while 2 other categories carry the remainder. The 6.5 average consequence score is above the beat benchmark of 6.3 in the same window. Central Drugs Standard Control Organisation (CDSCO) appears in 4 tracked Healthcare stories published from March 15, 2026 through July 27, 2026.
Computed from the 4 stories linked to this entity, with beat comparisons drawn from all 510 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Central Drugs Standard Control Organisation (CDSCO). Shared-story counts are live from our verified record — not editorial picks.
Target Milestone
Goal to reach $50 billion market size and 10-12% global market share.
Contempt Notice Issued
Justice Sachin Datta issues formal notice to CDSCO seeking an explanation for the delay.
Rollout of Production Linked Incentive schemes for high-end medical equipment.
Chintan Shivir
Department of Commerce holds strategic brainstorming to boost exports.
Contempt Petition Filed
Petitioners move court alleging CDSCO failed to meet the review deadline.
Initial Court Order
Delhi HC directs CDSCO to evaluate safety of diabetes drugs for weight loss.
Policy Launch
National Medical Device Policy 2023 is officially notified.
India's proposed licensing reform cuts wait times by 25 days for medium-risk and 15 days for high-risk devices, accelerating domestic production and improving healthcare access in a $13 billion market heavily dependent on imports.
Source: thehindubusinessline.com · livemint.com
Eli Lilly's RET inhibitor Tanstrive hits the Indian market at Rs 2.15 lakh per 14-day course, promising targeted therapy for advanced solid tumors but raising urgent questions about affordability, insurance coverage, and diagnostic capacity in the country's strained healthcare system.
Source: Business News India · Mint
The Delhi High Court has issued a contempt notice to India's drug regulator, CDSCO, for failing to comply with judicial orders to evaluate the safety of diabetes drugs used off-label for weight loss. This escalation signals a growing legal intolerance for regulatory delays amidst a global surge in GLP-1 receptor agonist demand.
The Indian Department of Commerce has convened a 'Chintan Shivir' to overhaul the nation's medical device export framework. This strategic brainstorming session aims to address regulatory hurdles and incentivize domestic manufacturing to position India as a global med-tech hub.
Source: oklahomacitysun.com · russiaherald.com
Central Drugs Standard Control Organisation (CDSCO) is linked from 4 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
